Published in J Infect Dis on January 22, 2007
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS (2007) 4.89
Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sex Transm Dis (2009) 2.30
Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. J Infect Dis (2008) 2.21
Prevalence and predictors of HIV infection among female sex workers in Kaiyuan City, Yunnan Province, China. Int J Infect Dis (2008) 2.05
Structural details and composition of Trichomonas vaginalis lipophosphoglycan in relevance to the epithelial immune function. Glycoconj J (2008) 1.69
Prevalence of Trichomonas vaginalis and coinfection with Chlamydia trachomatis and Neisseria gonorrhoeae in the United States as determined by the Aptima Trichomonas vaginalis nucleic acid amplification assay. J Clin Microbiol (2012) 1.68
An expanded inventory of conserved meiotic genes provides evidence for sex in Trichomonas vaginalis. PLoS One (2007) 1.67
Unique vaginal microbiota that includes an unknown Mycoplasma-like organism is associated with Trichomonas vaginalis infection. J Infect Dis (2013) 1.56
Intravaginal practices, vaginal infections and HIV acquisition: systematic review and meta-analysis. PLoS One (2010) 1.47
Current issues and considerations regarding trichomoniasis and human immunodeficiency virus in African-Americans. Clin Microbiol Rev (2009) 1.46
STI management and control in North America IUSTI region. Sex Transm Infect (2011) 1.38
Trichomoniasis and HIV interactions: a review. Sex Transm Infect (2013) 1.36
Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women. Clin Infect Dis (2008) 1.31
Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators. PLoS One (2011) 1.28
Genital tract leukocytes and shedding of genital HIV type 1 RNA. Clin Infect Dis (2008) 1.25
Mobility, risk behavior and HIV/STI rates among female sex workers in Kaiyuan City, Yunnan Province, China. BMC Infect Dis (2010) 1.23
Trichomonas vaginalis genital infections: progress and challenges. Clin Infect Dis (2011) 1.22
Trichomonas vaginalis infection in women who submit self-obtained vaginal samples after internet recruitment. Sex Transm Dis (2011) 1.21
Acceptability of self-testing for trichomoniasis increases with experience. Sex Transm Infect (2011) 1.18
Endobiont viruses sensed by the human host - beyond conventional antiparasitic therapy. PLoS One (2012) 1.17
Time from first intercourse to first sexually transmitted infection diagnosis among adolescent women. Arch Pediatr Adolesc Med (2009) 1.17
Extensive genetic diversity, unique population structure and evidence of genetic exchange in the sexually transmitted parasite Trichomonas vaginalis. PLoS Negl Trop Dis (2012) 1.14
Screening for genital and anorectal sexually transmitted infections in HIV prevention trials in Africa. Sex Transm Infect (2008) 1.12
Glyceraldehyde-3-phosphate dehydrogenase is a surface-associated, fibronectin-binding protein of Trichomonas vaginalis. Infect Immun (2009) 1.11
Microsatellite polymorphism in the sexually transmitted human pathogen Trichomonas vaginalis indicates a genetically diverse parasite. Mol Biochem Parasitol (2010) 1.11
Trichomonas vaginalis exosomes deliver cargo to host cells and mediate host∶parasite interactions. PLoS Pathog (2013) 1.11
Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009-2010. Emerg Infect Dis (2012) 1.10
Modeling the impact of Trichomonas vaginalis infection on HIV transmission in HIV-infected individuals in medical care. Sex Transm Dis (2012) 1.10
A prospective study of risk factors for herpes simplex virus type 2 acquisition among high-risk HIV-1 seronegative women in Kenya. Sex Transm Infect (2009) 1.06
Modern diagnosis of Trichomonas vaginalis infection. Sex Transm Infect (2013) 1.06
Sexually transmitted infections among HIV-1-discordant couples. PLoS One (2009) 1.06
Non-sexual transmission of Trichomonas vaginalis in adolescent girls attending school in Ndola, Zambia. PLoS One (2011) 1.06
The role of bacterial vaginosis and trichomonas in HIV transmission across the female genital tract. Curr HIV Res (2012) 1.05
Stepwise diagnosis of Trichomonas vaginalis infection in adolescent women. J Clin Microbiol (2008) 1.05
Use of nucleic acid amplification testing for diagnosis of anorectal sexually transmitted infections. J Clin Microbiol (2012) 1.03
Trichomonas vaginalis infection: can we afford to do nothing? J Infect Dis (2008) 1.03
Counseling and Harm Reduction Centers for Vulnerable Women to HIV/AIDS in Iran. Iran J Public Health (2013) 1.02
A Trich-y question: should Trichomonas vaginalis infection be reportable? Sex Transm Dis (2013) 1.02
Neglected parasitic infections in the United States: trichomoniasis. Am J Trop Med Hyg (2014) 1.02
Prevalence of Trichomonas vaginalis infection among young reproductive age women in India: implications for treatment and prevention. Sex Health (2009) 1.01
Bacterial vaginosis and risk for Trichomonas vaginalis infection: a longitudinal analysis. Sex Transm Dis (2011) 1.00
The mercaptopyruvate sulfurtransferase of Trichomonas vaginalis links cysteine catabolism to the production of thioredoxin persulfide. J Biol Chem (2009) 1.00
Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies. Infect Dis Obstet Gynecol (2011) 1.00
Correlation between HIV and sexual behavior, drug use, trichomoniasis and candidiasis among female sex workers in a Mekong Delta province of Vietnam. AIDS Behav (2008) 0.99
Observation of probable persistent, undetected Trichomonas vaginalis infection among HIV-positive women. Clin Infect Dis (2010) 0.99
Partnership concurrency status and condom use among women diagnosed with Trichomonas vaginalis. Womens Health Issues (2008) 0.99
Neighborhood social disorganization and the acquisition of trichomoniasis among young adults in the United States. Am J Public Health (2011) 0.96
Simple and inexpensive point-of-care tests improve diagnosis of vaginal infections in resource constrained settings. Trop Med Int Health (2009) 0.96
Bacterial vaginosis and the risk of trichomonas vaginalis acquisition among HIV-1-negative women. Sex Transm Dis (2014) 0.96
Characteristics and predictors of women who obtain rescreening for sexually transmitted infections using the www.iwantthekit.org screening programme. Int J STD AIDS (2013) 0.95
Co-occurrence of Trichomonas vaginalis and bacterial vaginosis among HIV-positive women. Sex Transm Dis (2011) 0.94
Epidemiology of curable sexually transmitted infections among women at increased risk for HIV in northwestern Tanzania: inadequacy of syndromic management. PLoS One (2014) 0.94
Genetic characterization of Trichomonas vaginalis isolates by use of multilocus sequence typing. J Clin Microbiol (2012) 0.93
Characterization of the Trichomonas vaginalis surface-associated AP65 and binding domain interacting with trichomonads and host cells. BMC Microbiol (2007) 0.93
Trichomonas vaginalis vaginitis in obstetrics and gynecology practice: new concepts and controversies. Obstet Gynecol Surv (2013) 0.91
Genetic diversity of Trichomonas vaginalis clinical isolates determined by EcoRI restriction fragment length polymorphism of heat-shock protein 70 genes. Am J Trop Med Hyg (2009) 0.91
A prospective cohort study comparing the effect of single-dose 2 g metronidazole on Trichomonas vaginalis infection in HIV-seropositive versus HIV-seronegative women. Sex Transm Dis (2013) 0.90
Vaginal microbiota and sexually transmitted infections that may influence transmission of cell-associated HIV. J Infect Dis (2014) 0.90
Trichomonas vaginalis contact-dependent cytolysis of epithelial cells. Infect Immun (2013) 0.89
Correlates of incident Trichomonas vaginalis infections among African American female adolescents. Sex Transm Dis (2014) 0.89
The association between Trichomonas infection and incarceration in HIV-seropositive and at-risk HIV-seronegative women. Sex Transm Dis (2011) 0.89
A recently transferred cluster of bacterial genes in Trichomonas vaginalis--lateral gene transfer and the fate of acquired genes. BMC Evol Biol (2014) 0.86
STI in remote communities: improved and enhanced primary health care (STRIVE) study protocol: a cluster randomised controlled trial comparing 'usual practice' STI care to enhanced care in remote primary health care services in Australia. BMC Infect Dis (2013) 0.85
Comparative transcriptomic and proteomic analyses of Trichomonas vaginalis following adherence to fibronectin. Infect Immun (2012) 0.85
Randomized Trial of Periodic Presumptive Treatment With High-Dose Intravaginal Metronidazole and Miconazole to Prevent Vaginal Infections in HIV-negative Women. J Infect Dis (2014) 0.85
Trichomonas vaginalis in selected U.S. sexually transmitted disease clinics: testing, screening, and prevalence. Sex Transm Dis (2013) 0.85
Genetic identity and differential gene expression between Trichomonas vaginalis and Trichomonas tenax. BMC Microbiol (2009) 0.85
Inhibitory effects of Thai plants beta-glycosides on Trichomonas vaginalis. Parasitol Res (2008) 0.85
Prevalence of 3 sexually transmitted infections in a pediatric emergency department. Pediatr Emerg Care (2015) 0.84
Loss to follow-up as a competing risk in an observational study of HIV-1 incidence. PLoS One (2013) 0.84
Performance of a rapid self-test for detection of Trichomonas vaginalis in South Africa and Brazil. J Clin Microbiol (2013) 0.83
The Role of Sexually Transmitted Infections in HIV-1 Progression: A Comprehensive Review of the Literature. J Sex Transm Dis (2013) 0.83
A 15-year study of the impact of community antiretroviral therapy coverage on HIV incidence in Kenyan female sex workers. AIDS (2015) 0.83
Establishing and sustaining a healthy vaginal environment: analysis of data from a randomized trial of periodic presumptive treatment for vaginal infections. J Infect Dis (2011) 0.82
Reversible association of tetraspanin with Trichomonas vaginalis flagella upon adherence to host cells. Cell Microbiol (2012) 0.82
Prevalence and predictors of trichomonas infection in newly incarcerated women. Sex Transm Dis (2012) 0.82
Detection of Trichomonas vaginalis DNA by use of self-obtained vaginal swabs with the BD ProbeTec Qx assay on the BD Viper system. J Clin Microbiol (2014) 0.82
A new rapid molecular point-of-care assay for Trichomonas vaginalis: preliminary performance data. Sex Transm Infect (2013) 0.81
Incidence of sexually transmitted infections among hazardously drinking women after incarceration. Womens Health Issues (2011) 0.81
Changes in the contribution of genital tract infections to HIV acquisition among Kenyan high-risk women from 1993 to 2012. AIDS (2015) 0.80
Epidemiology of undiagnosed trichomoniasis in a probability sample of urban young adults. PLoS One (2014) 0.80
Biological impact of recurrent sexually transmitted infections on HIV seroconversion among women in South Africa: results from frailty models. J Int AIDS Soc (2015) 0.80
Substance use patterns and factors associated with changes over time in a cohort of heterosexual women at risk for HIV acquisition in the United States. Drug Alcohol Depend (2014) 0.80
Getting trichy: tools and approaches to interrogating Trichomonas vaginalis in a post-genome world. Trends Parasitol (2012) 0.79
Prevalence and factors associated with Trichomonas vaginalis infection among high-risk women in Los Angeles. Sex Transm Dis (2013) 0.79
Histamine and TNF-alpha release by rat peritoneal mast cells stimulated with Trichomonas vaginalis. Parasite (2011) 0.79
Genetic diversity of Trichomonas vaginalis reinfection in HIV-positive women. Sex Transm Infect (2013) 0.79
Novel trichomonacidal spermicides. Antimicrob Agents Chemother (2011) 0.79
A Review of Evidence-Based Care of Symptomatic Trichomoniasis and Asymptomatic Trichomonas vaginalis Infections. Clin Infect Dis (2015) 0.78
The association between oral contraceptives, depot-medroxyprogesterone acetate, and trichomoniasis. Sex Transm Dis (2009) 0.78
Estimating age-dependent per-encounter chlamydia trachomatis acquisition risk via a Markov-based state-transition model. J Clin Bioinforma (2014) 0.78
Mechanisms of Tritrichomonas foetus Pathogenicity in Cats with Insights from Venereal Trichomonosis. J Vet Intern Med (2016) 0.78
Development of PCR assays for detection of Trichomonas vaginalis in urine specimens. J Clin Microbiol (2013) 0.78
Auranofin inactivates Trichomonas vaginalis thioredoxin reductase and is effective against trichomonads in vitro and in vivo. Int J Antimicrob Agents (2016) 0.78
The Pathogenesis of Human Cervical Epithelium Cells Induced by Interacting with Trichomonas vaginalis. PLoS One (2015) 0.77
T. vaginalis Infection Is Associated with Increased IL-8 and TNFr1 Levels but with the Absence of CD38 and HLADR Activation in the Cervix of ESN. PLoS One (2015) 0.77
Trichomonas vaginalis: treatment questions and challenges. Expert Rev Anti Infect Ther (2012) 0.77
Oral HHV-8 replication among women in Mombasa, Kenya. J Med Virol (2014) 0.77
The incidence of Trichomonas vaginalis infection in women attending nine sexually transmitted diseases clinics in the USA. Sex Transm Infect (2015) 0.77
Prevalence and predictors of sexually transmitted infections in hazardously-drinking incarcerated women. Women Health (2012) 0.77
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet (2010) 16.90
Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis (2011) 10.96
Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study. Lancet HIV (2015) 4.33
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66
Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS (2011) 3.61
What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr (2012) 3.44
Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One (2011) 3.27
Vulnerability of women in an African setting: lessons for mother-to-child HIV transmission prevention programmes. AIDS (2002) 3.22
Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS (2007) 3.14
Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis (2012) 3.06
HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis (2007) 2.87
The Medical Education Partnership Initiative: PEPFAR's effort to boost health worker education to strengthen health systems. Health Aff (Millwood) (2012) 2.84
Acceptability of medical male circumcision among uncircumcised men in Kenya one year after the launch of the national male circumcision program. PLoS One (2011) 2.79
Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med (2011) 2.76
Combination HIV prevention: significance, challenges, and opportunities. Curr HIV/AIDS Rep (2011) 2.72
Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. AIDS (2010) 2.70
HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res Hum Retroviruses (2002) 2.68
Vaginal washing and increased risk of HIV-1 acquisition among African women: a 10-year prospective study. AIDS (2006) 2.67
Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis (2006) 2.65
Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One (2010) 2.48
Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women. J Infect Dis (2004) 2.47
Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med (2013) 2.44
Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS (2007) 2.44
HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr (2014) 2.43
CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa. PLoS One (2009) 2.37
Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. PLoS One (2011) 2.36
The impact of early monitored management on survival in hospitalized adult Ugandan patients with severe sepsis: a prospective intervention study*. Crit Care Med (2012) 2.29
Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission. J Acquir Immune Defic Syndr (2009) 2.26
Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. J Infect Dis (2008) 2.21
Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infect Dis (2013) 2.18
Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol (2009) 2.16
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS (2009) 2.15
Female-to-male infectivity of HIV-1 among circumcised and uncircumcised Kenyan men. J Infect Dis (2005) 2.12
Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med (2012) 2.06
Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women. J Acquir Immune Defic Syndr (2010) 2.01
HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS (2007) 1.99
High HIV testing uptake and linkage to care in a novel program of home-based HIV counseling and testing with facilitated referral in KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr (2013) 1.97
Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. Curr Opin Infect Dis (2012) 1.97
Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. J Virol (2003) 1.96
Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data meta-analysis. PLoS Med (2011) 1.89
HIV-1 prevention for HIV-1 serodiscordant couples. Curr HIV/AIDS Rep (2012) 1.83
Evidence for frequent reinfection with human immunodeficiency virus type 1 of a different subtype. J Virol (2005) 1.77
Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis. Lancet HIV (2015) 1.77
The influence of hormonal contraceptive use on HIV-1 transmission and disease progression. Clin Infect Dis (2007) 1.75
Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial. J Infect Dis (2004) 1.74
Plasma viral loads during early HIV-1 infection are similar in subtype C- and non-subtype C-infected African seroconverters. J Infect Dis (2013) 1.74
Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection. J Virol (2003) 1.72
Association between cervical shedding of herpes simplex virus and HIV-1. AIDS (2002) 1.64
Cervicovaginal HIV-1-neutralizing immunoglobulin A detected among HIV-1-exposed seronegative female partners in HIV-1-discordant couples. AIDS (2012) 1.64
Impact of five years of peer-mediated interventions on sexual behavior and sexually transmitted infections among female sex workers in Mombasa, Kenya. BMC Public Health (2008) 1.64
Implementing voluntary medical male circumcision for HIV prevention in Nyanza Province, Kenya: lessons learned during the first year. PLoS One (2011) 1.61
Contribution of HIV-1 infection to acquisition of sexually transmitted disease: a 10-year prospective study. J Infect Dis (2004) 1.61
Will circumcision provide even more protection from HIV to women and men? New estimates of the population impact of circumcision interventions. Sex Transm Infect (2010) 1.60
Circumcision preference among women and uncircumcised men prior to scale-up of male circumcision for HIV prevention in Kisumu, Kenya. AIDS Care (2011) 1.58
A prospective study of contraceptive use among African women in HIV-1 serodiscordant partnerships. Sex Transm Dis (2010) 1.57
An empiric risk scoring tool for identifying high-risk heterosexual HIV-1-serodiscordant couples for targeted HIV-1 prevention. J Acquir Immune Defic Syndr (2013) 1.55
Identification of modifiable factors that affect the genetic diversity of the transmitted HIV-1 population. AIDS (2004) 1.55
Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection. AIDS (2008) 1.55
HIV‐exposed seronegative commercial sex workers show a quiescent phenotype in the CD4+ T cell compartment and reduced expression of HIV‐dependent host factors. J Infect Dis (2010) 1.54
Successful increase in contraceptive uptake among Kenyan HIV-1-serodiscordant couples enrolled in an HIV-1 prevention trial. AIDS (2009) 1.54